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Abstract
HemaMax, a recombinant human interleukin-12 (IL-12), is under development to address an unmet medical need for
effective treatments against acute radiation syndrome due to radiological terrorism or accident when administered at least
24 hours after radiation exposure. This study investigated pharmacokinetics, pharmacodynamics, and efficacy of m-
HemaMax (recombinant murine IL-12), and HemaMax to increase survival after total body irradiation (TBI) in mice and
rhesus monkeys, respectively, with no supportive care. In mice, m-HemaMax at an optimal 20 ng/mouse dose significantly
increased percent survival and survival time when administered 24 hours after TBI between 8–9 Gy (p,0.05 Pearson’s chi-
square test). This survival benefit was accompanied by increases in plasma interferon-c (IFN-c) and erythropoietin levels,
recovery of femoral bone hematopoiesis characterized with the presence of IL-12 receptor b2 subunit–expressing myeloid
progenitors, megakaryocytes, and osteoblasts. Mitigation of jejunal radiation damage was also examined. At allometrically
equivalent doses, HemaMax showed similar pharmacokinetics in rhesus monkeys compared to m-HemaMax in mice, but
more robustly increased plasma IFN-c levels. HemaMax also increased plasma erythropoietin, IL-15, IL-18, and neopterin
levels. At non-human primate doses pharmacologically equivalent to murine doses, HemaMax (100 ng/Kg and 250 ng/Kg)
administered at 24 hours after TBI (6.7 Gy/LD50/30) significantly increased percent survival of HemaMax groups compared to
vehicle (p,0.05 Pearson’s chi-square test). This survival benefit was accompanied by a significantly higher leukocyte
(neutrophils and lymphocytes), thrombocyte, and reticulocyte counts during nadir (days 12–14) and significantly less weight
loss at day 12 compared to vehicle. These findings indicate successful interspecies dose conversion and provide proof of
concept that HemaMax increases survival in irradiated rhesus monkeys by promoting hematopoiesis and recovery of
immune functions and possibly gastrointestinal functions, likely through a network of interactions involving dendritic cells,
osteoblasts, and soluble factors such as IL-12, IFN-c, and cytoprotectant erythropoietin.
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Introduction
Use of ionizing radiation or nuclear devices as weapons of
terrorism is now recognized as a major public health threat. In the
event of a nuclear detonation, terrorist radiological (e.g., ‘‘dirty’’)
bomb, or attack on a nuclear power plant in a populated area,
mass casualties will occur that will be in the need of immediate
medical attention [1]. At exposures approximating 4 Gy, it is
estimated that 50% of individuals will die within 60 days unless
there is medical intervention [2]. The majority of deaths that occur
from exposures of 2–10 Gy will result from the combined effects of
immune, hematopoietic, and gastrointestinal (GI) failure, as these
are the most radiosensitive tissues [1–3]. To date, there are no
FDA approved therapeutic agents capable of increasing the
chance for survival by simultaneously promoting or accelerating
the recovery of the immune, hematopoietic and gastrointestinal
compartments following radiation injury.
In the event of a radiation disaster or act of terrorism affecting a
large civilian population, the goal would be to provide a potent
frontline therapy that increases the chance for survival of the
exposed, or potentially exposed, individuals. One of the challenges
in such events is that medical care and treatments will not be
available immediately following radiation exposure. It is envi-
sioned that it will take 24 hours or more to mobilize medical teams
and necessary life-saving drugs and equipment to the scene of a
radiation disaster [4].
Since medical care will not be immediately available, a medical
intervention capable of increasing the chance for survival as a
frontline therapy would have to be efficacious when administered at
protractedtime pointsfollowingradiationexposure.Thisisindeed a
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apoptosis to rapidly dividing cells in radiosensitive organs, such as
the peripheral blood, bone marrow, and GI tract, starting
immediately after radiation exposure [1,2]. Moreover, the chance
of successfully providing life-saving treatment to the exposed
individualsdecreasesexponentiallyfollowingradiationinjury.Thus,
the effectiveness of providing countermeasure treatments that could
alleviate damage caused by radiation decreases rapidly with time.
Given this challenge, there has been a search for radio-
mitigation drugs that can increase the chance for survival following
radiation exposure to sensitive tissues such as the immune system,
bone marrow, and GI tract Numerous cytokines proteins and
small molecules,are under evaluation to to assess their respective
radiomitigation potential . For example Johnson et al [5] report on
a small molecule cyclin-dependent kinase inhibitor which shows
radiomitigation in mice when administered 20 hours after
irradiation. Protein drugs based upon the bacterial flagellin
protein have been shown to be radioprotective at administration
prior to radiation [6] or up to four hours post-irradiation [7], but
not at 24 hours post-irradiation [7]. Recombinant human growth
hormone has been reported to confer increased survival in mice
when treated for five consecutive days when administered first up
to 12 hours after irradiation [8]. Reviews by Singh and Yadav [9],
He ´rodin and Drouet [10], Weiss and Landauer [11], and Dumont
et al [12] provide further information on radioprotectants and
mitigants.. To date, there are no reports of any of these agents
conferring increased survival at 24 hours or longer post radiation
exposure, either in mice or non-human primates.
HemaMax is a recombinant human interleukin-12 (IL-12)
preparation that is currently being developed for use against acute
radiation syndrome in humans. Previously, we have investigated the
radioprotective properties of a prototype preparation, m-Hema-
Max, a recombinant mouse IL-12, following intravenous adminis-
tration. We found that m-HemaMax was able to dramatically
increase survival in mice following exposure to lethal doses of TBI
when it was administered at a single, low dose, either 24 hours
before or within 1 hour after radiation exposure [13,14]. Moreover,
multilineage recovery of peripheral blood cell counts via stimulation
by m-HemaMax, namely white blood cells, red blood cells and
platelets, was observed in both normal and tumor-bearing mice
exposed to sublethal TBI [13,14]. In these radioprotection studies,
m-HemaMax showed a remarkable ability to reconstitute the bone
marrow compartment following ablation [13,14]. Overall, these
data suggested that the activity of m-HemaMax in these model
systems is initiated at the level of primitive cells, likely hematopoietic
and non-hematopoietic stem cells, residing in the bone marrow
compartment, and that activation of these primitive cells leads to
regeneration of the bone marrow compartment following radio-
ablation or radiosuppression [13,14].
IL-12 is a heterodimeric cytokine, comprising both p40 and p35
subunits, that is well-known for its role in immunity [15]. In
numerous reports spanning about two decades, IL-12 has been
shown to have an essential role in the interaction between the
innate and adaptive arms of immunity by regulating inflammatory
responses, innate resistance to infection, and adaptive immunity
[15]. Endogenous IL-12 is required for resistance to many
pathogens and to transplantable and chemically induced tumors.
The hallmark effect of IL-12 in immunity is its ability to stimulate
the production of interferon-gamma (IFN-c) from natural killer
(NK) cells, macrophages and T cells [15]. Further, several in vitro
studies in the early-mid nineties reported that IL-12 is capable of
stimulating hematopoiesis synergistically with other cytokines
[16–20]. The hematopoiesis-promoting activity of IL-12 appears
to be due to a direct action on bone marrow stem cells as these
studies used highly purified progenitors or even single cells. The
role of IFN-c in the hematopoietic activity of IL-12 is not clear as
several studies have linked both the promotion and suppression of
hematopoiesis to IFN-c [21–27]. The potent effect of IL-12 in
mitigating radiation injury following exposure to lethal doses of
radiation was previously unknown.
Since we previously found that m-HemaMax was highly
effective when administered shortly after TBI, we attempted to
utilize a more stringent model of radiation exposure to investigate
the ability of m-HemaMax and HemaMax to increase survival
when administered at protracted time points post radiation in mice
and non-human primates (NHP), respectively. In a model of
radiomitigation, where single, low doses of m-HemaMax in mice
or HemaMax in NHP are administered subcutaneously at
24 hours or longer post irradiation, we now show that HemaMax
can provide potent mitigation of radiation injury to multiple
tissues, including the immune, bone marrow, and GI compart-
ments, leading to significant increases in survival. These results are
reported herein for both murine and NHP radiomitigation models
in the complete absence of supportive care. To our knowledge, this
is the first report showing potent radiomitigation effects of a
therapeutic agent in mice and NHP at protracted time points post
radiation, such as 24 hours or longer, following acute ionizing
radiation exposure.
Materials and Methods
Ethics Statement
Mice studies were carried out in BATTS Laboratories (North-
ridge, CA, USA; Animal Welfare Assurance Number (AWAN)
from the Office of Laboratory Animal Welfare (OLAW): A4475-
01), the Roy E. Coats Research Laboratories (University of
California, Los Angeles, CA, USA; AWAN from OLAW: A3196-
01), or LAB Research, Inc. (Laval, Que ´bec, Canada; AWAN from
OLAW: A5525-01). All procedures were reviewed and approved
by the Institutional Animal Care and Use Committees (IACUC) of
BATTS Laboratories (permit number: 01012011), Roy E. Coats
Research Laboratories, and LAB Research, Inc., (permit number:
2009-2665). Each of these institutions is accredited by the
Association for the Assessment and Accreditation of Laboratory
Animal Care (AAALAC) and the American Association of
Laboratory Animal Care. During the study, care and use of
animals were conducted in accordance with principles outlined in
the Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health (publication No: 85-23,
revised 1996) and the Guide to the Care and Use of Experimental
Animals published by the Canadian Council on Animal Care.
Care anduse ofNHPwereinaccordance withprinciples outlined
in the current Guide to the Care and Use of Experimental Animals
published by the Canadian Council on Animal Care, the Guide for
the Care and Use of Laboratory Animals published by the Institute
of Laboratory Animal Resources, and the recommendations of the
Weatherall report for The Use of Non-Human Primates in
Research (December 2006). All procedures for NHP studies were
reviewed and approved by the IACUC of LAB Research, Inc.,
(permit numbers: 2009-1243 and 2009-1253). The NHP irradiation
was approved by the Canadian Nuclear Safety Committee
(radiation permit number: 3572637). The LAB Research, Inc., is
an OLAW assured and AAALAC accredited facility. During the
study, all efforts were made to minimize suffering.
m-HemaMax and HemaMax
m-HemaMax (recombinant murine IL-12) was purchased from
Peprotech (Rocky Hill, NJ, USA) or provided by SBH Sciences
HemaMax for Acute Radiation Syndrome
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(recombinant human IL-12) was provided by SBH Sciences
(Natick, MA, USA) exclusively to Neumedicines. In the initial
mouse survival studies, lyophilized m-HemaMax was dissolved in
phosphate buffer saline (PBS), pH=7.2. In all other studies, m-
HemaMax and HemaMax were dissolved in a proprietary
formulation containing trehalose, Tween 20, and sodium phos-
phate, pH=5.6 (P5.6TT). Studies in mice and rhesus monkeys
utilized m-HemaMax and HemaMax, respectively. PBS was used
as vehicle in the initial mouse survival studies as indicated. P5.6TT
was used as vehicle in all other studies.
Mice
Mouse survival studies were carried out at either BATTS
Laboratories (Northridge, CA, USA; HHS OLAW A4475-01) or
the Roy E. Coats Research Laboratories (University of California,
Los Angeles, CA, USA; HHS OLAW A3196-01). Mouse bone
marrow isolations were carried out at BATTS Laboratories.
Female C57BL/6 mice were obtained from The Jackson
Laboratory (Sacramento, CA, USA), and male mice from Harlan
Laboratories (Placentia, CA, USA), or were bred at the Roy E.
Coats Research Laboratories (Coats mice) Coats mice are
gnobiotic, and consequently,are have a lesser less radiosensitive
than the Harlan mice. Differences in radiation doses in
experiments using the different mice consequently differed with
higher radiation amounts used in the Coats mice experiments.
Coats mice exposed to radiation doses of 8.6, 8.8 and 9.0 Gy in
these studies whereas Harlan mice were subjected to 8 Gy unless
otherwise specified. Mouse pharmacokinetic (PK) and pharmaco-
dynamic (PD) studies and gastrointestinal (GI) tissue isolations
were carried out at LAB Research, Inc. (Laval, Que ´bec, Canada;
HHS OLAW A5525-01). Male C57BL/6 mice were obtained
from Charles River Canada, Inc. (Saint-Constant, Que ´bec,
Canada). In PK/PD studies involving radiation Charles River
mice were subjected to 8.6 Gy TBI (LD100/30). At all study sites,
mice were maintained in quarantine for at least one week. Mice
used in the survival and PK/PD studies were 9 weeks to 10 weeks
old and weighed approximately 20 g with no signs of disease.
Survival Studies in Mice
At day 0, TBI was carried out at a lethal dose of 8.0 Gy (Harlan
mice) or 9.0 Gy (Coats mice) –doses that are expected to cause
death in about 90% of animals within 30 days–using GammacellH
40 with
137Cs source (Theratronics, Ontario Canada with a rate of
71 cGy/min in Coats mice studies and 85 cGy/min in the Harlan
mice studies) in a specially constructed ‘‘pie-box’’ designed to keep
mice in the center of the irradiator for even distribution of
radiation. Mice received subcutaneous injections of either vehicle
or m-HemaMax at the indicated doses at 24 hours, 48 hours,
and/or 72 hours after irradiation. Mice were monitored for
survival up to day 30. During this period, mice were deprived of all
supportive care, including antibiotics, to increase the stringency of
the survival protocol. The mice had access to food and acidified
water ad libitum.
Radiation dose dependency of the m-HemaMax effect was
evaluated in mice (n=10 per group; Coats mice), which were
irradiated at lethal doses of 8.6 Gy, 8.8 Gy, and 9.0 Gy, which
resulted in LD70/30,L D 90/30, and LD100/30, respectively. Animals
received vehicle or m-HemaMax at a dose of 20 ng/mouse
24 hours after TBI. Mice were monitored for survival up to day
30. No supportive care, including antibiotics, was allowed during
this period. The mice had access to food and acidified water
ad libitum.
Plasma PK and PD of m-HemaMax in Irradiated and Non-
Irradiated Mice
Mice (n=3 per group) received m-HemaMax subcutaneously at
a dose of 10 ng/mouse, 20 ng/mouse, 40 ng/mouse, or 200 ng/
mouse either in the absence of irradiation or 24 hours after an
LD100/30 (8.6 Gy; Charles River mice) of TBI. Two additional
control groups of animals (n=3 per group), which did not receive
m-HemaMax, were either not exposed to radiation or irradiated at
8.6 Gy. The concentrations of m-HemaMax and IFN-c were
determined in plasma from blood samples withdrawn at
45 minutes and 1.5, 3, 6, 12, 24, 48 and 72 hours after m-
HemaMax administration by enzyme-linked immunosorbent
assay (ELISA). Plasma erythropoietin (EPO) levels were measured
only at the 12 hour timepoint because of limited sample
availability.
Bone Marrow and GI Histopathology in Mice
For bone marrow histopathology studies, mice (n=2 per group)
were subjected to TBI at 8.0 Gy (Harlan mice, ,LD40/30 in this
experiment) and were subsequently administered either vehicle
(P5.6TT) or m-HemaMax (20 ng/mouse) subcutaneously at either
(a) 24 hours, (b) 24 hours and 2 days, (c) 24 hours and 3 days, (d)
24 hours and 4 days, or (e) 24 hours and 5 days after irradiation.
An additional group of mice (n=2) received HemaMax at
24 hours after TBI. Mice were sacrificed 12 days after irradiation,
and femoral bone marrow was provided as paraffin-embedded,
sectioned tissues by Cyto-Pathology Diagnostic Center, Inc
(Duarte, CA, USA).
For GI histopathology studies, mice (n=3 per group) received
vehicle (P5.6TT) or m-HemaMax subcutaneously at doses from
10 ng/mouse to 200 ng/mouse either in the absence of irradiation
or 24 hours after a TBI at 8.6 Gy (Charles River mice, LD100/30).
Mice were sacrificed 3 days after irradiation, and jejunum was
provided as paraffin-embedded, sectioned tissues by Cytopathol-
ogy Diagnostics Center, Inc. (Duarte, CA, USA).
Sectioned tissues were deparaffinized with xylene, rehydrated
with decreasing concentrations of ethanol, and subjected to the
heat-induced epitope retrieval (HIER) to recover antigens.
Endogenous peroxidase was inhibited with 0.3% H2O2, and
background staining was blocked with the Background Sniper
(Biocare Medical, LLC.; Concord, CA).
In the bone marrow histopathology studies, tissue sections were
incubated with either rabbit anti-mouse IL-12 receptor beta 2
subunit (IL-12Rb2) (Sigma; St Louis, MO), rabbit anti-mouse
osteocalcin (Millipore; Billerica, MA), a marker of osteoblasts, or
rabbit anti-mouse Sca-1 (Epitomics; Burlingame, CA), a marker of
hematopoietic stem cells. In the GI histopathology studies, tissue
sections were incubated with rabbit anti-mouse IL-12Rb2, or
rabbit anti-mouse leucine-rich-repeat-containing G-protein-cou-
pled receptor 5 (LGR5), a GI stem cell marker that is expressed
upon GI injury. After removing the primary antibodies, tissue
sections were incubated with peroxidase conjugated anti-rabbit
IgG (ImmPRESS; Vector Laboratories; Burlingame, CA). Red
coloring of peroxidase labeled cells developed following incubation
with AEC substrate (ImmPACT AEC; Vector Laboratories;
Burlingame, CA) and were counterstained with CAT Hematoxylin
(Biocare Medical, Concord, CA). Tissue sections were then
immersed in Vectamount (Vector Laboratories; Burlingame,
CA), covered with a cover slip, sealed with clear nail polish, and
visualized using an Olympus Compound microscope (Olympus
America, Inc; Center Valley, PA) at 1006magnification for bone
marrow sections and 4006for jejunum.
Co-expression of Sca-1 and IL-12Rb2 on hematopoietic stem
cells was evaluated by incubating bone marrow tissue sections first
HemaMax for Acute Radiation Syndrome
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followed by incubation with Rabbit on Rodent HRP-Polymer
(Biocare Medical; Concord, CA) and 3,39-diaminodbenzidine
substrate (Biocare Medical; Concord, CA). After treatment with
denaturing solution (Biocare Medical; Concord, CA), tissue
sections were incubated with rabbit anti-mouse IL-12Rb2 (Sigma;
St Louis, MO) followed by incubation with Rabbit on Rodent AP
polymer (Biocare Medical; Concord, CA) and Warp Red substrate
(Biocare Medical; Concord, CA). Tissue sections were then
counterstained in CAT Hematoxylin and visualized as described
above. Using this method, cells expressing Sca-1 and IL-12Rb2
were stained in brown and pink, respectively.
Non-Human Primates (NHP)
Male rhesus monkeys, Macaca mulatta, were purchased from
Worldwide Primates, Inc., (Miami, FL, USA). Animals of 3 to 4
years of age weighing 3.5 to 5.8 Kg were acclimatized for at least 7
weeks. All rhesus monkeys included in the experiments were in
good health by physical examination, were negative for Herpes B-
virus, simian immunodeficiency virus, simian T-lymphotropic
virus, and simian type retrovirus, and were vaccinated against
hepatitis A and measles. Animals were housed individually in
stainless steel monkey cages equipped with automatic watering
systems. The animal room environment was continuously
controlled for temperature (2163uC), humidity (30% to 70%),
light cycle (12 hours light:12 hours dark), and air change (10 to 15
air changes/hour). A standard certified commercial primate chow
was available to each monkey twice a day. Food was withdrawn
overnight prior to irradiation and necropsy. Animals were
acclimated to the various procedures with positive reinforcement
prior to study initiation. Health status was extensively evaluated to
ensure animals were in good condition for the studies. All animals
were provided prophylactic analgesia (buprenorphine) from day 5
to study completion. Specific euthanasia criteria were included in
each experimental protocol to minimize suffering. Continuous
clinical care (24 hours/7 days) were provided throughout the study
to ensure prompt intervention when needed. A team of technicians
and veterinarians trained in NHP medicine was responsible for
clinical monitoring and provided state-of-the-art medical care.
Allometric Dose Conversion From Mice to Rhesus Monkey
m-HemaMax doses that were found effective against lethal TBI
in mice were converted to their equivalent doses in rhesus monkey
based on body surface area [28]. Pharmacological equivalency of
the species-specific equivalent doses were evaluated in relation to
the HemaMax stimulation of IFN-c secretion from peripheral
blood mononuclear cells (PBMC) in vitro and the PK and PD
characteristics of HemaMax in vivo.
Isolation of CD14- PBMC and Quantification of IFN-c
Secretion
Human PBMC collected by apheresis were purchased from
AllCells (Emeryville, CA, USA). Mouse and rhesus monkey
PBMC were from Bioreclamation (Liverpool, NY, USA). CD14-
PBMC were isolated as follows. Red blood cells were removed
from human PBMC by a single step gradient with Ficoll-Hypaque
premium (Density=1.077; GE Healthcare Lifesciences; Piscat-
away, NJ, USA) and from rhesus monkey and mouse PBMC by
lysis using ACK lysis buffer (Invitrogen; Carlsbad, CA, USA). To
remove IL-12-secreting endogenous monocyte populations, hu-
man and rhesus monkey PBMCs were labeled with mouse anti-
human CD14PE antibody (AbD Serotec; Raleigh, NC, USA), and
mouse PBMCs were labeled with mouse anti-mouse CD14PE
(AbD Serotec; Raleigh, NC, USA). The excess antibody was
removed and cells were incubated with magnetic beads conjugated
with anti-PE antibody (Miltenyi Biotec; Auburn, CA, USA). After
removing the excess antibody, CD14+ cells were captured by
adsorption to an LD column (Miltenyi Biotec; Auburn, CA, USA)
immobilized in a magnetic field (Quadro MACSH; Miltenyi
Biotec; Auburn, CA, USA). CD14- cells in the flow-through were
collected, and those from humans were resuspended at a density of
14610
6 cells/mL in cold fetal bovine serum (FBS) containing 20%
dimethyl sulfoxide whereas those from rhesus monkey and mouse
were resuspended at a density of 2.14610
6 cells/mL in RPMI
medium containing 10% FBS and antibiotics. IFN-c was
quantified by ELISA in supernatants from 2.5610
5 human,
rhesus monkey, or mouse CD14- PBMC incubated with various
concentrations (range: 0 to 1000 pM) of HemaMax or m-
HemaMax for 16 hours at 37uC. All experiments were carried
out in triplicate. The half maximal effective concentration (EC50)
of IL-12 for stimulating IFN-c secretion was calculated by
SoftMax ProH software version 3.1 (Molecular Devices; Sunny-
vale, CA, USA) using a 4-parameter logistic fit.
Plasma PK and PD of HemaMax in NHP
Radiation-naive rhesus monkeys received HemaMax subcuta-
neously at a dose of either 250 ng/Kg (n=3) or 1000 ng/Kg
(n=3). The concentrations of HemaMax, IFN-c, and other
potential biomarkers of HemaMax were determined by ELISA in
plasma samples withdrawn prior to the HemaMax administration
and at 2, 6, 12, 18, 24, 30, 36, 48, 72, 96, 120, 144 and 168 hours
after HemaMax administration.
IL-12Rb2 Expression in NHP and Human Bone Marrow
and Small Intestine
Paraffin-embedded, sectioned tissues from NHP and human
femoral bone marrow and jejunum/ileum were obtained from
Biomax, Inc (Rockville, MD). NHP and human tissue sections
were immunohistochemically stained for IL-12Rb2 using rabbit
anti-human IL-12Rb2 according to the procedures described in
the section for mice histopathology studies.
Survival Studies in NHP
At day 0, rhesus monkeys acclimated to the restraining
procedure with positive reinforcement were subjected to TBI at
an LD50/30 of 6.7 Gy. Irradiation was performed in two half-dose
fractions (anteroposterior and posteroanterior) at the rate of 55
cGy/minute using a Cobalt-60 unit (Theratron 780; Theratronics;
Ontario, Canada). The irradiation dose was monitored with 2
dosimeters (Thermoluminescent or NanoDot dosimeters; Land-
auer Inc.; Glenwood, IL, USA) placed at the apex of the sternum
and at the corresponding level in the interscapular area of each
animal. Following TBI, animals were randomly assigned to receive
subcutaneously either (a) vehicle at 24 hours post TBI (n=8), (b)
100 ng/Kg of HemaMax at 24 hours post TBI (n=8), (c) 100 ng/
Kg of HemaMax at 24 hours and 7 days post TBI (n=8), (d)
250 ng/Kg of HemaMax at 24 hours post TBI (n=8), or (e)
250 ng/Kg of HemaMax at 24 hours and 7 days post TBI (n=8).
Animals were monitored for survival and clinical and physical
characteristics for up to day 30. The primary outcome measure
was the percentage of survival. Peripheral blood cell counts, body
weight, and clinical signs were evaluated as secondary outcome
measures.
During the study, blood transfusions or antibiotic use was
prohibited. Evidence of pain or discomfort was treated with
intramuscular buprenorphine (0.01 mg/Kg to 0.05 mg/Kg at
HemaMax for Acute Radiation Syndrome
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provided if animals presented with decreased appetite. Through-
out the study, clinical signs were monitored at least twice a day,
and complete blood counts and body weight were monitored once
every other day. Hematology samples were analyzed with an
automated hematology analyzer (Advia 120; Bayer Diagnostics;
Tarrytown, NY, USA). During the study, animals were euthanized
if they had respiratory distress, anorexia/decreased appetite
(complete anorexia for 3 days), weight loss (in excess of 20% of
baseline body weight in 72 hours), unresponsiveness to touch,
acute gross blood loss, generalized seizure, or abnormal vital signs.
The euthanized animals or those found dead were subjected to a
full macroscopic necropsy examination, including bacteriology
testing. All animals were euthanized at the end of the study on day 31.
Quantification of m-HemaMax and HemaMax and their
Biomarkers in Plasma
Blood samples from mice and rhesus monkeys were collected
into tubes containing ethylenediaminetetraacetic acid and were
kept on ice (,30 minutes) until centrifugation. Samples were
centrifuged at 15006 g for 10 minutes at 4uC. Plasma was
aliquoted and stored at 270uC until use. Plasma m-HemaMax,
HemaMax, and their potential biomarkers were assayed by
ELISA. The ELISA kits for mouse IL-12 (p70) and IFN-c were
obtained from BioLegend (San Diego, CA, USA), for NHP IL-12
from BioLegend (San Diego, CA, USA), MabTech (Mariemont,
OH, USA), and R&D Systems (Minneapolis, MN, USA), for NHP
IFN-c from MabTech (Mariemont, OH, USA), for human EPO,
IL-18, and IL-15 from R&D Systems (Minneapolis, MN, USA),
and for Neopterin from GenWay (San Diego, CA, USA). All
assays were carried out in triplicate according to the manufactur-
ers’ instructions except those for NHP IL-12 in which an in-house
reference standard was used instead of the standard provided by
the manufacturer.
Statistical Analyses
Data were presented as mean 6 standard error (SE). Between-
group differences in survival were evaluated with Kaplan-Meier
survival analysis, followed by the Mantel-Cox Test for survival
time and Pearson’s chi-square test for percentage of survival.
Between-group differences in blood cell counts were evaluated by
analysis of variance (ANOVA), except for the number of platelet
counts dropping below the transfusion level of 20,000 platelets/ml,
which was analyzed by Pearson’s chi-square test. Between group
differences in clinical signs were evaluated by ANOVA. A P value
of ,.05 was defined as the level of statistical significance.
Results
Single, Low Doses of m-HemaMax Administered 24
Hours Post TBI Increased Survival in Irradiated Mice
In the initial studies, 87.5% of mice receiving a subcutaneous
ostensible dose of 100 ng/mouse of m-HemaMax at 24 hours and
72 hours post 8 Gy TBI survived for up to 30 days, whereas only
14% of vehicle mice survived this same lethal 8 Gy TBI by day 30
(P,0.005) (Figure 1a). The actual m-HemaMax dose delivered in
these studies was 10 ng/mouse (see below for a discussion
concerning dose delivery). Subsequent studies evaluated whether
a single dose of m-HemaMax was sufficient to provide similar
radiomitigation effect. In these studies, a single, ostensible dose of
m-HemaMax (300 ng/mouse; the actual delivered dose was 20–
30 ng/mouse; see below for a discussion concerning dose delivery)
significantly increased survival time when administered at either
24 hours (P=.001), 48 hours (P=.02), or 72 hours (P,.03 ) after a
9 Gy TBI resulting in the LD100/30 (Figure 1b). Mice treated with
m-HemaMax had a higher percentage of survival when m-
HemaMax was administered at 24 hours compared to 48 hours
post TBI (Figure 1b). The difference in percentage of survival
between the vehicle group and mice treated with m-HemaMax at
24 hours post TBI was statistically significant (0% vs 60%,
respectively; P,.05) (Figure 1b).
It is noteworthy that in these early studies, very low, nanogram
quantities of m-HemaMax were reconstituted in PBS. However,
ELISA analysis of the reconstituted m-HemaMax demonstrated
that the actual dose delivered was approximately 10% of the
intended dose, most likely because of m-HemaMax sticking to
surfaces of vials and syringes. Therefore, in the subsequent studies,
m-HemaMax was reconstituted in P5.6TT, which increased dose
delivery to nearly 90% of the intended dose. With this improve-
ment, a single m-HemaMax dose of 2 ng/mouse or 18 ng/mouse
provided significantly higher radiomitigation than did vehicle
against a TBI dose of 7.9 Gy that resulted in an LD85/30 when
administered 24 hours post radiation (Figure 1c). At the dose of
2 ng/mouse, m-HemaMax significantly increased percentage of
survival (P,.02) and marginally increased survival time (P=.07)
compared to vehicle. At the dose of 18 ng/mouse, m-HemaMax
significantly increased both the percentage of survival (P,.005) and
survival time (P,.03) compared to vehicle. Animals treated with m-
HemaMax at a higher dose, such as 160 ng/mouse, had modestly
longer survival time compared to the vehicle group but a lower
percentage of survival relative to animals treated with the 2 ng/
mouse or 18 ng/mouse dose (data not shown). Thus, these findings
indicate that a dose of approximately 20 ng/mouse is the optimal,
efficacious dose of m-HemaMax to increase survival.
To evaluate the relationship between the radiation dose and
percentage of survival upon treatment with m-HemaMax, 3
ascending doses of radiation (8.6, 8.8, and 9.0 Gy corresponding to
resultant LD 70/30,L D90/30, and LD 100/30, respectively) were
tested in mice. m-HemaMax at a dose of 20 ng/mouse
administered 24 hours after TBI significantly increased survival
time at all 3 levels of radiation intensities (Figure 2). The
percentage of survival in animals treated with vehicle was 20%
at 8.6 Gy (LD70/30), 10% at 8.8 Gy (LD90/30), and 0% at 9.0 Gy
(LD100/30) (Figure 2). Compared to the vehicle groups, treatment
with m-HemaMax resulted in significantly higher percentage of
survival of 80% at LD70/30, 60% at LD90/30, and 70% at LD100/30
(P,.05 for all) (Figure 2), demonstrating a radiation dose-
independence for m-HemaMax administration at 24 hours post
TBI within the selected window of radiation exposures. Remark-
ably, comparable percentages of survival after a single, fixed dose
of m-HemaMax at increasing radiation doses indicate that the
efficacy of m-HemaMax is not decreased with increasing radiation
dose. These data suggest that at radiation doses where immune,
bone marrow, and GI damage overlap, m-HemaMax can provide
mitigation of injury in all three radiosensitive tissues, thereby
leading to an increase in survival that is relatively independent of
radiation dose within a certain window of exposure.
Plasma PK and PD of m-HemaMax in Irradiated and Non-
Irradiated Mice
Plasma concentrations of m-HemaMax and IFN-c were
determined over 72 hours in 2 groups of mice, which received
increasing doses of m-HemaMax (from 10 ng/mouse to 200 ng/
mouse) either in the absence of irradiation or 24 hours after an
approximate LD90/30 of TBI (8.6 Gy). The m-HemaMax doses
lower than 10 ng/mouse were not evaluated because of the
limitations in m-HemaMax detection. m-HemaMax was detected
in all plasma from animals receiving m-HemaMax (Figure 3), but
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did not receive m-HemaMax regardless of the presence or absence
of irradiation (data not shown).
The exposure to m-HemaMax (area under the curve last;
AUClast) increased dose proportionally from 10 ng/mouse to
40 ng/mouse regardless of the presence or absence of irradiation
(Figure 3 and Table 1). Interestingly, maximum plasma concen-
trations (Cmax) of m-HemaMax were consistently higher in
irradiated mice as compared to non-irradiated mice at all doses
(Figure 3). The exposure to m-HemaMax (AUClast) at the dose of
200 ng/mouse was disproportionately higher than those at the
lower doses (10 ng/mouse to 40 ng/mouse), suggesting that PK
properties of m-HemaMax are non-linear at the higher dose
ranges(Table 1).In the doserangeof10 ng/mouse to 40 ng/mouse,
m-HemaMax reached Cmax in 3 hours to 6 hours and was
eliminated with a half-life of approximately 4 hours (Table 1).
m-HemaMax administration increased plasma IFN-c concen-
tration with a lag time at all study doses (Figure 3). Of significance,
IFN-c production was not abrogated in irradiated mice (Figure 3).
In fact, for all m-HemaMax doses, except the optimal dose of
20 ng/mouse dose, plasma IFN-c levels were higher in irradiated
mice compared to non-irradiated mice (Figure 3). The exposure to
IFN-c dose proportionally increased as a function of increasing m-
HemaMax dose from 10 ng/mouse to 200 ng/mouse (data not
shown). Importantly, IFN-c was not detected in plasma of mice,
which did not receive m-HemaMax regardless of the presence or
absence of irradiation.
Since preliminary studies had shown that co-administration of
m-HemaMax and EPO in a certain regimen led to a substantial
increase in survival following lethal radiation exposure (data not
shown), we sought to assess whether m-HemaMax may affect
plasma levels of EPO in irradiated and non-irradiated mice.
Figure 1. m-HemaMax administered at least 24 hours after TBI increased survival time of irradiated mice. (a) Animals received vehicle
or m-HemaMax at an ostensible dose of 100 ng/mouse at 24 hours and 72 hours after a TBI of 8 Gy (LD86/30). (b) Animals received vehicle or a single,
ostensible dose of 300 ng/mouse of m-HemaMax at 24 hours, 48 hours, or 72 hours after a TBI of 9 Gy (LD100/30). (c) Animals received vehicle or a
single low dose of m-HemaMax (2 ng/mouse or 18 ng/mouse) at 24 hours after a TBI of 7.9 Gy (LD85/30). Vehicle and m-HemaMax were injected
subcutaneously. Vehicle was PBS in (a) and (b) and P5.6TT in (c). The delivered m-HemaMax dose was estimated to be 10 ng/mouse in (a) and 30 ng/
mouse in (b) because subsequent studies showed that the actual m-HemaMax dose delivered was approximately 10% of the intended dose, most
likely due to m-HemaMax sticking to surfaces of vials and syringes.
doi:10.1371/journal.pone.0030434.g001
HemaMax for Acute Radiation Syndrome
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e30434Figure 2. Efficacy of m-HemaMax in increasing survival is not dependent on radiation dose in mice. Animals were subjected to TBI at
ascending radiation doses of 8.6 Gy (LD70/30), 8.8 Gy (LD90/30), and 9.0 Gy (LD100/30) and subsequently received m-HemaMax at a dose of 20 ng/mouse
24 hours after irradiation. Mice were monitored for survival up to day 30. Vehicle was P5.6TT.
doi:10.1371/journal.pone.0030434.g002
Figure 3. m-HemaMax administration increased plasma m-HemaMax and IFN-c levels in irradiated and non-irradiated mice. Animals
received m-HemaMax subcutaneously at a dose of (a) 10 ng/mouse, (b) 20 ng/mouse, (c) 40 ng/mouse, or (d) 200 ng/mouse in the absence of
irradiation or at 24 hours after an LD90/30 of TBI. The plasma concentrations of m-HemaMax and IFN-c were determined by ELISA in blood samples
withdrawn at the indicated times. The y-axis scale in (d) is 8 times greater than those in (a) and (b) and 5 times greater than that in (c). n=3 per
timepoint in each group.
doi:10.1371/journal.pone.0030434.g003
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could be measured in only 1 early timepoint, 12 hours after m-
HemaMax administration (Figure 4). In non-irradiated, untreated
animals, EPO was detectable in plasma at low pg/mL range
(Figure 4). Irradiation increased plasma EPO levels nearly linearly
up to 80 hours post TBI, suggesting that EPO is a part of the
physiological response to radiation injury (data not shown).
Remarkably, however, at the optimal dose of 20 ng/mouse at
12 hours post administration (36 hours post radiation exposure),
m-HemaMax substantially increased plasma EPO concentrations
over the radiation-induced levels (Figure 4), indicating that m-
HemaMax potentiates the EPO-mediated physiological response
to radiation, but only at or near the optimal dosing level. It is
noteworthy that, at this optimal dose, plasma EPO levels were also
increased in non-irradiated mice (Figure 4). It remains to be
further evaluated as to whether the EPO response to m-HemaMax
administration occurs at a narrow window of m-HemaMax dose
range because a highly potentiated EPO response was observed
only after administration of the 20 ng/mouse dose (Figure 4). It is
interesting to note that the IFN-c response appeared to be
subdued at the 20 ng/mouse dose of m-HemaMax, the dose at
which EPO was upregulated by m-HemaMax, as compared to the
other doses assessed. In a mice model of multiple sclerosis,
administration of EPO was reported to downregulate the
inflammatory response, and in particular, suppress IFN-c [29].
Thus, these findings suggest that the increased plasma EPO levels
may play a role in the suppression of plasma IFN-c levels in
irradiated mice that received m-HemaMax at the dose of 20 ng/
mouse (Figure 3b), leading to a decrease in the inflammatory
response to radiation.
Other biomarkers of m-HemaMax administration were also
screened, namely tumor necrosis factor-alpha (TNF- a and stem
cell factor (SCF), but the plasma levels for these factors were found
to be below the limit of quantitation.
Table 1. Plasma PK Characteristics of m-HemaMax in Irradiated and Non-Irradiated Mice.
Cmax (pg/mL) AUClast (pg.h/mL) Tmax (hours) t1/2 (hours)
m-HemaMax dose, ng/mouse NR R NR R NR R NR R
10 82.8 96.4 628 728 6 3 na na
20 129.5 217.2 1453 2364 3 6 3.7 3.5
40 257.8 308.8 2720 2701 6 3 3.5 4.2
200 1428 2332 21008 37059 3 1.5 4.8 7.2
Animals received m-HemaMax subcutaneously at a dose of 10 ng/mouse, 20 ng/mouse, 40 ng/mouse, or 200 ng/mouse in the absence of irradiation or at 24 hours
after an LD90/30 of TBI. The plasma concentrations of m-HemaMax were determined by ELISA.
AUC=area under the curve; Cmax=maximum plasma concentrations; NR=no irradiation; R=irradiation; TBI=total body irradiation; Tmax=time to achieve the
maximum plasma concentration; t1/2=half life.
doi:10.1371/journal.pone.0030434.t001
Figure 4. Optimal m-HemaMax dose of 20 ng/mouse increased plasma EPO concentration in irradiated mice. Animals received m-
HemaMax subcutaneously at a dose of (a) 10 ng/mouse, (b) 20 ng/mouse, (c) 40 ng/mouse, or (d) 200 ng/mouse in the absence of irradiation or at
24 hours after an LD90/30 of TBI. The plasma concentrations of EPO were determined by ELISA in blood samples withdrawn at 12 hours after m-
HemaMax administration.
doi:10.1371/journal.pone.0030434.g004
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Mitigated Radiation-induced Injury in Murine Bone
Marrow and Small Intestine
Femoral bone marrow from irradiated mice treated with vehicle
or m-HemaMax $24 hours after TBI (LD30/30) were stained for
IL-12Rb2 and evaluated for histological signs of recovery from
radiation-induced injury at 12 days post TBI. As a control, bone
marrow from non-irradiated, untreated mice was characterized
with the presence of IL-12Rb2–expressing hematopoietic stem
cells, identified by co-staining for Sca-1 (a murine stem cell
marker; see below), immature megakaryocytes with lobulated
nuclei surrounded by a narrow rim of cytoplasm, matured
megakaryocytes with lobulated nuclei and voluminous cytoplasm,
and myeloid progenitor cells in the metamyelocyte stage
(Figure 5a).
Bone marrow from mice treated only with vehicle and subjected
to an LD30/30 of TBI (8.0 Gy) was characterized with minimal
signs of hematopoietic regeneration and the complete lack of IL-
12Rb2–expressing cells after 12 days following irradiation
(Figure 5b). In contrast, mice treated with various dosing regimens
of m-HemaMax showed varying levels of hematopoietic reconsti-
tution, which was characterized with the presence of IL-12Rb2–
expressing myeloid progenitors, megakaryocytes, and osteoblasts
(Figure 5c–f). Mice treated with HemaMax, which has been
demonstrated to not cross react with the murine IL-12 receptor,
showed some signs of regeneration, however, lacked megakaryo-
cytes (Figure 5g). For mice treated with HemaMax, however, no
increase in the survival was observed, as compared with the vehicle
control group (data not shown).
In order to further evaluate as to whether morphologically
identified cells were indeed hematopoietic stem cells and
osteoblasts, bone marrow tissue sections were stained for the
corresponding markers, respectively, Sca-1 and osteocalcin. As
depicted in Figure 6 a and b, IL-12Rb2 expression was observed
on cells that were morphologically identified as hematopoietic
stem cells and osteoblasts, which expressed Sca-1 and osteocalcin,
respectively. Co-expression of IL-12Rb2 and Sca-1 in bone
marrow tissue sections was also evaluated by a dual staining
approach. As depicted in Figure 6c, a discrete subset of
hematopoietic stem cells were co-stained for the presence of both
IL-12Rb2 and Sca-1. Both immature and mature megakaryocytes
expressing IL-12Rb2 was also evident in the bone marrow tissue
sections (Figure 6c). These findings suggest a direct role for IL-12
signaling pathway in hematopoietic reconstitution.
Similar to hematopoietic stem cells and osteoblasts in femoral
bone marrow, mice jejunal crypts expressed IL-12Rb2 (Figure 7a).
In the absence of irradiation, m-HemaMax administration at
doses up to 200 ng/mouse did not cause injury in jejunal crypts
(Figure 7b, upper panel). Exposure to TBI (8.6 Gy), however,
resulted in substantial jejunal damage 3 days after irradiation, as
evidenced by the widespread expression of LGR5, a GI stem cell
marker shown to be expressed upon chemotherapy-induced GI
injury [30–32]. Remarkably, administration of m-HemaMax at
the low dose range of 10 ng/mouse to 40 ng/mouse dose-
dependently mitigated radiation-induced jejunal damage, with
no LGR5 expression evident at the optimal, efficacious dose of
20 ng/mouse (Figure 7b, lower panel). On the other hand, m-
HemaMax at the high dose of 200 ng/mouse exacerbated jejunal
injury (Figure 7b, lower panel). As observed with the m-HemaMax
dose ranges for optimal increases in survival, these data point to a
window of opportunity for mitigation of radiation injury by m-
HemaMax in a very low dose range of the drug that is also
effective in alleviating bone marrow damage.
Allometric Dose Conversion From Mice to NHP
In order to achieve a similar radiomigitation effect in rhesus
monkey, doses that are pharmacologically equivalent to those
given to mice should be administered to rhesus monkeys. Based on
the Food and Drug Administration (FDA) guidelines [28], the
optimal 20 ng/mouse dose (1000 ng/Kg) and a non-optimal
80 ng/mouse (4000 ng/Kg) dose in mouse translate, respectively,
to the 250 ng/Kg and 1000 ng/Kg doses in rhesus monkey.
However, eliciting a pharmacologically equivalent response at
species-specific equivalent doses depends on several factors
including similar drug exposure and specific reactivity with the
primary target site in both species. Therefore, prior to evaluating
the efficacy of the radiomitigation effects of HemaMax in NHP,
we first examined the pharmacological equivalency of the species-
specific equivalent doses.
HemaMax and m-HemaMax Potently Stimulated IFN-c
Secretion From Human, Rhesus Monkey, and Mouse
CD14- PBMC In Vitro
Target reactivity to HemaMax was evaluated by comparing
EC50 values of HemaMax and m-HemaMax for stimulating the
secretion of IFN-c from CD14- PBMC. As reported previously
[33], we observed that HemaMax did not cross-react with PBMC
isolated from mouse and rat (EC50.1000 pM). In contrast,
HemaMax potently stimulated IFN-c secretion from both human
and rhesus monkey PBMC with EC50 values of, respectively,
2.5160.51 pM and 1.0560.10 pM. The EC50 value of m-
HemaMax for stimulating IFN-c secretion from mouse PBMC
was 0.3560.29 pM. These findings suggest that the reactivities of
monkey and mouse PBMC to, respectively, HemaMax and m-
HemaMax are similar in relation to IFN-c secretion in vitro.
Plasma PK of HemaMax in Rhesus Monkeys
Plasma PK of HemaMax was examined in rhesus monkeys
following a single administration of HemaMax at two doses of
250 ng/Kg and 1000 ng/Kg in the absence of irradiation.
Following administration, the exposure (AUClast) to HemaMax
increased in proportion to dose (Table 2). The AUClast of
HemaMax in rhesus monkey was perfectly superimposed linearly
for the AUClast of m-HemaMax in mice over the dose range of
10 ng/mouse to 80 ng/mouse (Figure 8), suggesting that the
species-specific equivalent doses calculated from mice studies
provided similar drug exposure in monkeys. The 200 ng/mouse
dose was not included in this analysis as it appeared that m-
HemaMax exhibits different PK characteristics at higher doses
(Table 1).
HemaMax at a single dose of 250 ng/Kg or 1000 ng/Kg was
well tolerated and was not associated with overt signs of toxicity,
except for the occurrences of transient decreases in appetite in the
1000 ng/Kg group.
HemaMax Administration Increased Plasma
Concentrations of IFN-c, IL-15, IL-18, Neopterin, and EPO
In Non-Irradiated Rhesus Monkeys
In monkeys, subcutaneous administration of HemaMax ap-
peared in plasma shortly after administration and was not
detectable after 72 hours (Figure 9a). Moreover, as observed in
mice with m-HemaMax, HemaMax was observed to increase
plasma IFN-c concentration in proportion to dose (Figure 9a).
Temporal kinetics of IFN-c response in rhesus monkey was,
however, different from mouse in that the IFN-c response was
delayed for a longer period of time and was much higher in
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detected in plasma of monkeys that did not receive HemaMax.
Of other potential biomarkers, the exposure (AUClast) to IL-18
and EPO was increased by 2.4-fold and 5.1-fold, respectively, as
the HemaMax dose was increased from 250 ng/Kg to 1000 ng/
Kg (Figure 9b). HemaMax also increased plasma IL-15 and
neopterin concentrations, peaking at 72 hours and 96 hours,
respectively, post HemaMax administration (Figure 9c). In
contrast to previous reports in humans [34–37], the plasma
concentrations of rhesus monkey TNF-a and IL-10 were not
changed. Numerous other potential biomarkers were screened, but
were found to be below the limit of quantification.
NHP and Human Bone Marrow and Small Intestine
Express IL-12Rb2
The expression of IL-12Rb2 in non-irradiated NHP (rhesus
monkeys) and human femoral bone marrow and jejunum/ileum
was evaluated by immunohistochemistry. As depicted in
Figure 10a, NHP, as well as human, progenitor cells and
megakaryocytes expressed IL-12Rb2. The expression of IL-
12Rb2 was also found on osteoblasts/osteoclasts from the bone
marrow. However, it could not be determined as to whether these
cells were osteoblasts and/or osteoclasts because the donated
tissues were smears and did not include periosteum or other bone
tissues. Bone marrow adipocytes were not stained positive for IL-
12Rb2.
In the small intestine, IL-12Rb2 was most commonly expressed
in crypts (Figure 10b). It is not known if IL-12Rb2-expression in
the intestinal crypt is localized to Paneth cells, multipotent stem
cells, or both. IL-12Rb2 expression was also noted in lymphoid
cells populating the lamina propria and submucosal regions
(Figure 10b). Mucin secreting goblet cells did not express IL-
12Rb2. Both crypt and lamina propria IL-12Rb2-expressing cells
could represent multifunctional mesenchymal-origin myofibro-
blasts that can serve as crypt shape-forming cells that also occupy
both a stem cell niche and act as non-professional antigen
presenting cells to immunomodulatory cells in the lamina propria.
Further studies will establish the cellular and functional identity of
IL-12Rb2-expressing cells in intestinal crypts and their supportive
role in intestinal regeneration after radiation exposure.
HemaMax Administration Increased Survival in Irradiated,
Unsupported Rhesus Monkeys
In a pilot study of 40 animals, the percent survival of rhesus
monkeys exposed to an LD50/30 of TBI ( 6.7 Gy) was determined
following treatment with 100 ng/Kg or 250 ng/Kg of HemaMax
administered at 24 hours or at 24 hours and 7 days post TBI. This
study was conducted in the absence of any supportive care,
including antibiotics. The doses of HemaMax were chosen based
on PK/PD studies in rhesus monkeys and were equivalent to m-
HemaMax doses of 8 ng/mouse and 20 ng/mouse, respectively.
As is depicted in Figure 11a, HemaMax at both doses, following
either single or two administrations, migitated death due to
irradiation to the same extent. Overall percentages of survival
were 71% in the 100 ng/Kg single dose group (n=7) and 75% in
all other groups receiving HemaMax (n=8) compared to 50% in
the vehicle group. Between-group differences in percentage of
survival were not statistically significant, most likely because of the
small number of animals in each group (n=8), but also because
both HemaMax doses were likely within the efficacious dose
range. However, analysis of the percent survival regardless of the
HemaMax dosing regimen indicated that when pooled together,
monkeys treated with HemaMax had significantly higher percent
survival than those receiving vehicle (75% vs 50%, respectively;
P=.05) (Figure 11b).
Changes in Blood Cell Counts of Irradiated, Unsupported
Rhesus Monkeys Following HemaMax Administration
Three analyses were conducted to assess differences in blood cell
counts during the study period. In the first analysis, where blood
cell counts were analyzed from day 1 up to day 30, animals treated
with HemaMax had significantly higher numbers of leukocytes
and thrombocytes at days 12 and 14, around the nadir, for the
100 ng/Kg and 250 ng/Kg doses, as compared to animals treated
with vehicle (Figure 12).
In a second analysis, where blood cell counts were analyzed
from day 1 up to day 14, the day before any animals died, animals
treated with HemaMax had higher platelets counts compared to
animals treated with vehicle (P=.079 for the 250 ng/Kg group
and P=.02 for the 100 ng/Kg twice dosing group) during nadir
(days 12 to 14). Additionally, in comparison to the vehicle group,
animals treated with HemaMax had significantly higher counts of
leukocytes (P,.01 for the 250 ng/Kg group and P,.04 for the
100 ng/Kg twice dosing group) and reticulocytes (P,.04 for the
250 ng/Kg group and P,.001 for the 100 ng/Kg group) during
nadir (days 12 to 14). The same trend was apparent for neutrophil,
basophil, and lymphocyte counts, but they did not reach
acceptable levels of statistical significance.
In a third analysis the number of animals that reached clinically
low platelet counts during the study was assessed. This analysis
revealed a remarkable difference between the vehicle and
HemaMax groups in the number of platelet counts dropping
below a threshold level of 20,000 platelets/mL, a level generally
necessitating platelet transfusion. In the HemaMax 250 ng/Kg
group, only 4 out of 16 (25%) platelet counts at the nadir (day 12
to day14) dropped below the transfusion threshold of less than
20,000 platelets/mL whereas 12 out of 15 (80%) platelet counts for
the vehicle animals were below the threshold level during the same
period of time (P=.007).
Taken altogether, these findings indicate that HemaMax
increases leukocytes, platelet, and reticulocyte counts just prior
to the days on which animals begin to die from radiation toxicity
(day 13, Figure 11a). Interestingly, vehicle-treated animals that
survived up to day 30 also had quick recovery of blood cell counts,
which were statistically indistinguishable from those in the
HemaMax groups. These findings suggest that mortality likely
occurs in animals that do not show a strong blood cell recovery
around the nadir day(s). The validity of this hypothesis was
Figure 5. m-HemaMax promotes hematopoietic recovery in irradiated mice. Representative sections of femoral bone marrow from non-
irradiated, untreated mice that were stained for IL-12Rb2 (orange color) are shown in (a). Animals were subjected to TBI (8.0 Gy) and subsequently
received vehicle (P5.6TT) or m-HemaMax (20 ng/mouse) subcutaneously at the indicated times post irradiation (b–f). An additional group of mice
received HemaMax at 24 hours after TBI (g). Femoral bone marrow was immunohistochemically stained for IL-12Rb2 (orange color) 12 days after
irradiation. While bone marrow from mice treated with vehicle lacked IL-12Rb2–expressing cells and showed no signs of hematopoietic regeneration
(b), mice treated with m-HemaMax showed hematopoietic reconstitution and the presence of IL-12Rb2–expressing megakaryocytes, myeloid
progenitors, and osteoblasts (c–f). Mice treated with HemaMax showed IL-12Rb2–expressing osteoblasts but lacked megakaryocytes (g).
Magnification=1006.
doi:10.1371/journal.pone.0030434.g005
HemaMax for Acute Radiation Syndrome
PLoS ONE | www.plosone.org 11 February 2012 | Volume 7 | Issue 2 | e30434Figure 6. Mice bone marrow hematopoietic stem cells, osteoblasts, and megakaryocytes express IL-12Rb2. Tissue sections obtained 30
days (a and c) and 12 days (b) after TBI (according to the protocol described in Figure 5) were stained immunohistochemically for IL-12Rb2 (a and b,
upper panels), markers of hematopoietic stem cells, Sca-1 (a, lower panel), and osteoblasts, osteocalcin (b, lower panel), or both IL-12Rb2 and Sca-1
(c). Also both immature and mature megakaryocytes showed intense immunohistochemical staining for the presence of IL-12Rb2 (c). Red arrows in
(a) indicate hematopoietic stem cells that express IL-12Rb2 while black arrows indicate those that do not express IL-12Rb2. In IL-12Rb2 and Sca-1
double staining (c) IL-12Rb2 is stained pink while Sca-1 is stained brown. The subpopulation of stem cells co-expressing IL-12Rb2 and Sca-1 as well as
subpopulations expressing only IL-12Rb2 or Sca-1 are indicated (c). Magnification=1006.
doi:10.1371/journal.pone.0030434.g006
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the mortality status, i.e., those surviving up to day 30 versus
animals dying after day 12. In this analysis, the blood cell counts
on the day before death was taken for animals that died after day
12. The comparison day for the surviving animals in each group
was the average day on which the decedents in a particular group
died (days 14 to 18). This analysis demonstrated that, regardless of
the particular treatment group, animals surviving up to day 30 had
significantly higher counts of platelets, neutrophils, leukocytes,
reticulocytes, and lymphocytes than those that died after day 12
(P,.001 to P,.05). When compared by treatment group, animals
treated with 100 ng/Kg HemaMax had significantly higher counts
of neutrophils, leukocytes, and lymphocytes than did those treated
with vehicle in both survivors and decedent groups (P,.001 for all
three cell types). In addition, animals treated with 100 ng/Kg
HemaMax had a numerically higher platelet and reticulocyte
counts. These findings suggest that HemaMax-induced increase in
blood cell counts around nadir may play a key role in promoting
survival following radiation exposure.
Clinical and Physical Characteristics of Irradiated,
Unsupported Rhesus Monkeys Following HemaMax
Administration
Animals receiving HemaMax at the dose of 100 ng/Kg (once or
twice) had consistently higher mean body weights than did those in
the vehicle group from days 14 to day 30 (Figure 13a). Animals
treated with HemaMax at the dose of 100 ng/Kg (once or twice)
or 250 ng/Kg (once) had less weight loss than did animals treated
with vehicle from days 14 to 30 (Figure 13 c and d). Although the
between group differences in body weight or weight loss were not
statistically significant, when the analysis of body weight loss was
limited to day 12—the approximate day for blood cell nadir and
the day after which animals began to die (Figure 11a)— the pooled
HemaMax-treated animals had significantly less body weight loss
Figure 7. m-HemaMax at low dose suppresses radiation-induced intestinal injury in mice. The IL-12Rb2 expression in jejunal crypts (a)
and the suppression of jejunal expression of LGR5 (b), a GI stem cell injury marker, are shown. Mice received vehicle (P5.6TT) or m-HemaMax
subcutaneously at the indicated doses either in the absence of irradiation or 24 hours after TBI (8.6 Gy). Three days after irradiation, jejunum tissues
were removed and immunohistochemically stained for IL-12Rb2 (a) or LGR5 (b). Representative images show LGR5 in brown as indicated with arrows.
Magnification=400.
doi:10.1371/journal.pone.0030434.g007
Table 2. Plasma Pharmacokinetic Characteristics of HemaMax in Non-Irradiated Rhesus Monkeys.
HemaMax dose, ng/Kg Cmax (pg/mL) AUClast (pg.h/mL) Tmax (hours) t1/2 (hours)
250 38.368.4 11926382 1063.5 20.4612.3
1000 193.3661.3 570861488 863.5 40.6624.1
Animals received HemaMax subcutaneously at a dose of either 250 ng/Kg or 1000 ng/Kg in the absence of irradiation. The plasma concentrations of HemaMax were
determined by ELISA.
AUC=area under the curve; Cmax=maximum plasma concentrations; Tmax=time to achieve the maximum plasma concentration; t1/2=half life.
doi:10.1371/journal.pone.0030434.t002
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respectively; P=.04). Logistic regression demonstrated that weight
loss after day 12 was a strong predictor of survival (P,.001). Other
clinical signs (appetite, physical activity, diarrhea, and feces color)
were not significantly different from the vehicle group, although
appetite and physical activity improved in HemaMax treated
animals, and the incidence of diarrhea and black or red feces
declined in the 250 ng/Kg twice dosing regimen group. However,
above-mentioned clinical signs did predict mortality after day 12
by logistic regression (P=.002 for decreased appetite, P,.001 for
decreased physical activity, P=.04 for incidence of diarrhea, and
P=.008 for incidence of red or black feces). Clinical signs of severe
deterioration and stress, including chronic anorexia, sunken eyes,
dehydration, hunched and/or crouching posture and weakness,
started approximately at day 14 with no remarkable between-
group differences in the incidence or onset. All adverse clinical
signs were consistent with acute radiation syndrome following
exposure to radiation.
Gross pathology along with organ and hemoculture bacteriol-
ogy evaluation was conducted for all animals, which died or were
euthanized before the end of study. There were no HemaMax–
related macroscopic lesions. The incidence of hemorrhage was
12.5% (1/8 animals) in the pooled animals treated with 100 ng/
Kg or 250 ng/Kg of HemaMax compared to 50% (2/4) in the
vehicle animals. In the vehicle group, all of the decedent animals
(4/8 animals) were found dead while only 1 animal in the
HemaMax groups was found dead and 8 animals were humanely
euthanized before the end of study. A diagnosis of septicemia was
confirmed by isolation of the same bacterial strain in at least 2
organs of all 13 animals.
In the vehicle group, 75% (3/4) found dead animals presented a
combination of bacteria most likely from the intestinal and
cutaneous flora and 25% (1/4) presented organ infections with
only bacteria most likely from the cutaneous bacterial flora. In the
various HemaMax-treated groups, 8 out of 9 animals (89%)
presented a combination of bacteria from the intestinal and
cutaneous flora, including 2 which also presented organ infections
with bacteria most likely from the environment. The other animal
(1/9) presented organ infections with only bacteria most likely
from the cutaneous flora. These results suggest that opportunistic
infections were present in all animals that died preterminally in
this animal model of acute radiation syndrome.
Discussion
Radiation toxicity caused by TBI dose-dependently implicates
immune, hematopoietic and the GI tissues, as these are the most
radiosensitive targets in the body. Lymphocytes are the most
sensitive cells to radiation toxicity and, at irradiation doses of .2
Gy, are the first to be depleted from circulation. The lymphocyte
loss is followed by a decline in granulocytes and then platelet levels
over a period of days. Acute-onset anemia may occur secondary to
hemorrhage [1,2]. At doses of .4 Gy, radiation adversely affects
GI epithelium/endothelium, and the resulting clinical manifesta-
tion is due to a combination of the hematopoietic and GI
toxicities, presenting with nausea, vomiting, diarrhea, headache,
fatigue, fever, and abdominal pain [1,2]. Death originating from
immune and hematopoietic toxicity occurs because of infection
due to impaired immunity and/or hemorrhage due to thrombo-
cytopenia, while death originating from GI toxicity is often
because of multisystem organ failure, overwhelming sepsis, and
complications of bleeding [2]. In the event of a radiological attack,
radiation mitigators with multi-tissue effects capable of alleviating
immune, hematopoietic and GI toxicities when administered after
radiation exposure, are needed to save lives.
Our findings demonstrate that HemaMax (this term is used
throughout this discussion to collectively include its prototype m-
HemaMax as well) mitigated death due to radiation-induced
toxicity in both mice and monkeys following administration of a
single, low dose. Importantly, in both mice and monkeys,
HemaMax increased survival when administered at protracted
timepoints post radiation exposure, such as 24 hours or longer, in
the absence of supportive care, including oral or topical
antibiotics. In irradiated mice and monkeys, HemaMax promoted
survival at various levels by stimulating the immune system in the
peripheral blood and extravascular spaces, promoting hematopoi-
etic regeneration in bone marrow, decreasing tissue injury in the
small intestine, and triggering a generalized anti-apoptotic and
anti-inflammatory effect throughout the body.
The optimal murine dose that provided these radiomitigation
effects is approximately 20 ng/mouse. This dose is ostensibly
lower than our previous reports for HemaMax efficacy in
radioprotection and as a hematological adjuvant in cancer therapy
[13,14]. However, the discrepancy is likely due to the use of
formulated protein in the present studies. Moreover, protracted
administration of HemaMax at 24 hours post irradiation appears
to act via a somewhat different mechanism as compared with our
previous studies where HemaMax was administered either before,
or shortly after, radiation exposure [13,14]. Evidence for this
statement comes from a comparison of the bone marrow recovery
in the current murine radiomitigation studies, as compared to
previous studies in mice [14,38]. In the current studies, bone
marrow recovery appeared to be much slower, likely due to the
timing of HemaMax administration (24 hours before TBI in
previous studies versus 24 hours after TBI in this study).
Further, in the current radiomitigation studies in mice, when
compared to irradiated control, HemaMax markedly decreased
the radiation induced expression of LRG5, a stem cell marker
which also serves as a marker of GI injury, when administered at
24 hours post radiation exposure. HemaMax, at doses from
10 ng/mouse to 40 ng/mouse administered 24 hours post TBI,
reduced radiation-induced LGR5 expression. In contrast, with
Figure 8. Similar exposures to m-HemaMax and HemaMax at
species-specific equivalent doses in mice and rhesus monkeys.
The plot of plasma AUClast of m-HemaMax versus the dose administered
to mice in the absence of irradiation was linear at doses from 10 ng/
mouse to 40 ng/mouse. The plasma AUClast of HemaMax at monkey
equivalent doses of 20 ng/Kg and 80 ng/Kg was in good agreement
with the extend of dose-dependent increases in m-HemaMax exposure
in mice.
doi:10.1371/journal.pone.0030434.g008
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appeared to exacerbate radiation-induced GI injury as evidenced
by an increase in LGR5 expression.. This finding may be consistent
with earlier reports that high doses of IL-12 exacerbated radiation
injury to the GI tract [14,38]. Data obtained in both mice (data not
shown) and rhesus monkeys show significant increases in body
weights for m-HemaMax and HemaMax-treated animals, respecti-
vely,after irradiation (Figure 13), thereby providing further support
for the protective GI effect of of HemaMax treatment.
Our findings that HemaMax can reduce radiation toxicity and
increase survival in mice was confirmed in monkeys. HemaMax
administered to rhesus monkeys at 24 hours post radiation
significantly increased survival (P=.05, pooled treated groups vs.
vehicle control). HemaMax-treated monkeys had significantly
higher numbers of platelets, leukocytes, and reticulocytes at the
nadir, had lower incidence of hemorrhage, and had higher body
weights from day 12 to day 30.
To provide perspective about the importance of body weight
changes, it is worth mentioning that weight loss after day 12 is a
strong predictor of survival (P,.001). The lack of statistically
significant between-group differences in the incidence of cause of
death from hemorrhage and decreases in body weight is likely
because of the small number of animals in each group. On the
other hand, if the change in body weight analysis was limited to
the blood cell nadir (day 12), just before animals began dying, the
pooled group analysis (all HemaMax-treated groups versus the
vehicle group) resulted in a statistically significant difference
(P=.04), while the individual HemaMax-treated groups were
marginally different from the vehicle group (P=.078). Moreover,
thrombocytopenia was less severe in animals treated with
HemaMax than in those treated with vehicle. Further, a
remarkable difference was observed between the vehicle and
HemaMax-treated groups in platelet counts dropping below the
threshold level of 20,000 platelets/mL, a level that generally
Figure 9. HemaMax administration increased plasma IFN-c, IL-18, EPO, IL-15, and neopterin concentrations in non-irradiated
rhesus monkeys. (a) Temporal kinetics of IFN-c relative to that of HemaMax. (b) Temporal kinetics of IL-18 and EPO. (c) Temporal kinetics of IL-15
and neopterin. Animals received HemaMax subcutaneously at a dose of either 250 ng/Kg or 1000 ng/Kg in the absence of irradiation. The plasma
concentrations of HemaMax, IFN-c, IL-18, EPO, IL-15, and neopterin were determined by ELISA in blood samples withdrawn at the indicated times.
n=3 per timepoint in each group, except for neopterin, which was n=1.
doi:10.1371/journal.pone.0030434.g009
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PLoS ONE | www.plosone.org 15 February 2012 | Volume 7 | Issue 2 | e30434Figure 10. NHP and human bone marrow and small intestine express IL-12Rb2. Tissues from NHP and human femoral bone marrow (a) and
jejunum/ileum (b) were immunohistochemically stained for IL-12Rb2. (a) Progenitor cells and megakaryocytes expressing IL-12Rb2 are shown.
Adipocytes did not express IL-12Rb2. (b) Intestinal crypts expressing IL-12Rb2 are shown. Lymphoid cells in the lamina propria and submucosal
regions also expressed IL-12Rb2. C=crypt; LP=lamina propria. Magnification was 406in (a) and 1006in (b).
doi:10.1371/journal.pone.0030434.g010
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Kg group, only 4 out of 16 (25%) platelet counts at the nadir (day
12 to day14) dropped below the transfusion threshold of less than
20,000 platelets/mL whereas 12 out of 15 (80%) platelet counts for
the vehicle animals were below the threshold during the same
period of time (P=.007). Thus, in spite of small number of animals
in the monkey study, statistically significant differences were
observed in several key survival-related parameters. These findings
are significant as, in our study, HemaMax was administered after
TBI, the earliest at 24 hours post irradiation—a window of time
considered minimally necessary for mobilization of medical
personnel and resources to the affected area. This is the first
study that demonstrates the potential of HemaMax as a life-saving
intervention in the event of a radiological disaster.
Our findings reported here provide evidence that when
administered as single, low doses after TBI, HemaMax mitigates
radiation-induced toxicity in at least three major systems affected
by radiation: the immune system, the bone marrow compartment,
and the GI tract. HemaMax protection of the GI tract,however,
remains to be confirmed in GI focused experiments implemented
at higher radiation levels. An additional event related to the
HemaMax mitigation of radiation toxicity is the stimulation of
anti-apoptotic/anti-inflammatory effects via release of EPO, a
known general protector of tissue against cytotoxic damage via
anti-apoptotic/anti-inflammatory mechanisms [74].
Several interdependent networks may underlie the radiomitiga-
tion effect of HemaMax. It is known that IL-12 is a central
regulator of cell-mediated immune responses and modulates the
synthesis and secretion of several immune mediators [39,40]. In
cancer patients, intraperitoneal/intravenous/subcutaneous ad-
ministration of IL-12 increased peritoneal/serum levels of IFN-c,
TNF-a, IL-10, IL-8, VEGF, IP-10, and neopterin [34–37]. In our
study, HemaMax administration dose-dependently increased
plasma IFN-c levels in both mice and monkeys. IFN-c orchestrates
many distinct cellular programs through transcriptional control
over large numbers of genes, resulting in heightened immune
surveillance and immune system efficiency against infection [41].
In addition to IFN-c, HemaMax increased plasma levels of EPO
in mice (IL-15, IL-18 and neopterin were not tested) and IL-15,
IL-18, neopterin, and EPO in monkeys. The lack of dose
proportional response with IL-15, IL-18 and neopterin is likely
due to saturation of target sites related to release of these
mediators. However, the lack of a dose proportional response for
EPO appears to be more related to an interplay between IFN-c
and EPO, as suggested by our data and the reports of others
[42,43]. In a previous report, administration of EPO has been
Figure 11. HemaMax initiated at least 24 hours after irradiation increased percentage of survival of unsupported monkeys.
Individual dosing groups (a) and the pooled HemaMax dosing group (b) are shown. Animals were subjected to an LD50/30 of TBI at day 0 and
subsequently received either vehicle (P5.6TT) or HemaMax subcutaneously at the indicated dosing regimens. Supportive care was prohibited during
the study. Animals were monitored for survival up to 30 days.
a One animal was excluded from the study due to a broken tooth.
doi:10.1371/journal.pone.0030434.g011
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an animal model of multiple sclerosis [29].
IL-15 and IL-18, alone and/or in combination, play important
roles in the development, homeostasis, and functions of CD4+ T
cells, CD8+ T cells, natural killer (NK) cells, and NK T cells [44–
46]. In synergism with IL-12, IL-18 stimulates the production of
IFN-c in T helper 1 cells [47]. Neopterin, an auto-oxidation
product of 7,8-dihydroneopterin, reflects IFN-c activity and, as a
corollary, is considered as an indicator of systemic immune
activation [48,49].
The current study is the first to demonstrate that HemaMax
stimulates EPO production in mice and NHP. This finding
suggests that EPO may play a central role in mediating the
radiomitigation activity of HemaMax. The role of EPO in
biological functions other than erythropoiesis has only recently
begun to unravel, primarily after finding EPO receptors on cells
other than erythroid progenitors, such as polymorphonuclear
leukocytes, megakaryocytes, and endothelial, myocardial, and
neuronal cells [50–55]. Accumulating evidence indicates that EPO
has immunomodulatory, neuroprotective, and cardioprotective
activities. EPO enhances cell viability, modulates surface antigen
expression, and increases IL-12 secretion in dendritic cells–the
most potent antigen presenting cells–suggesting that immunomod-
ulatory functions of EPO may partly be mediated through
dendritic cells, which in turn induce specific T cell responses
[56,57]. Cytoprotective effects of EPO have at least in part, been
linked to its antioxidant, anti-inflammatory and antiapoptotic
activities. In various models of cytotoxicity induced by toxicants,
ischemia, hypoxia, or oxidative stress, EPO increased cellular
antioxidant capacity and/or decreased oxidant injury in kidney,
neurons, and retinal pigment epithelial cells [58–62] while it
reduced apoptosis in neurons, vascular smooth muscle cells,
cardiomyocytes, and endothelial cells [63–66].
The underlying mechanisms of radiomitigation conferred by
exogenous HemaMax is now beginning to be revealed by the
findings of our current and previous studies, suggesting a
multilevel response orchestrated by exogenous delivery of
HemaMax (Figure 14). Current evidence suggests that HemaMax
triggers responses at, at least, 4 levels by directly activating IL-12
receptors (a) on immune cells in peripheral blood and bone
marrow (Level 1), (b) on hematopoietic stem cells and other key
cells of the bone marrow niche, such as osteoblasts (Level 2), (c) on
Figure 12. HemaMax administration decreased leukopenia (a) and thrombocytopenia (b) at nadir in irradiated, unsupported
rhesus monkeys. Animals were subjected to an LD50/30 of TBI at day 0. Animals received subcutaneously either vehicle (P5.6TT) or HemaMax at a
dose of 100 ng/Kg or 250 ng/Kg at 24 hours post TBI. Blood samples were withdrawn at the indicated times, and leukocytes and platelets were
counted by an automated hematology analyzer.
doi:10.1371/journal.pone.0030434.g012
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whereby EPO, a cytoprotective factor, is released following
radiation exposure (Figure 14).
The most immediate response is the HemaMax-induced Level 1
Response, which involves key radioresistant cells of the immune
system. At the very early stages following radiation exposure, most
immune cells undergo apoptosis with a rank order according to
their radiosensitivity (B cells.T regulatory cells.T helper cells.T
cytotoxic cells.T memory cells.NK cells) [4]. The immune cells
that are likely to remain functional at 24 hours or longer post
irradiation are those that are the least radiosensitive, namely NK
cells and differentiated cells, such as macrophages and dendritic
cells. Thus, HemaMax administered after radiation can initiate the
Level 1 response by promoting the proliferation and activation of
the surviving NK cells, macrophages, and dendritic cells [4,15].
The tridirectional cross-talk between NK cells, macrophages and
dendritic cells further promotes their maturation and expansion
via cytokines identified as biomarkers of the restoration of innate
immunity, namely IFN-c, IL-15, IL-18 and neopterin [49,67–69].
This tridirectional cross-talk further leads to the production of
endogenous IL-12 secreted from dendritic cells (Figure 14). As a
consequence, early immune competence is established via innate
immunity mechanisms following TBI. Continuous production of
endogenous IL-12 from pathogen-activated dendritic cells also
serves as a positive feedback loop and plays a key role in sustaining
the initial response to exogenous HemaMax, perhaps for weeks
after radiation exposure (Figure 14). Evidence for the continued
production of endogenous IL-12 following exogenous administra-
tion of HemaMax is the presence of IL-12Rb2 on hematopoietic
cells 12 days after TBI only in mice that were treated with
HemaMax.
HemaMax initiates the Level 2 Response through interaction
with the primary bone marrow cells involved in hematopoiesis. In
the bone marrow, residual hematopoietic stem cells, osteoblasts,
and megakaryocytes are likely the cell types that remain extant
and functional 24 hours following exposure to lethal doses of
radiation [70]. The presence of IL-12Rb2–expressing stem/
progenitor cells, megakaryocytes, and/or osteoblasts in bone
marrow from mice, NHP, and humans indicates that these cells
are direct targets of HemaMax. Through its receptors, HemaMax
Figure 13. Irradiated rhesus monkeys receiving HemaMax had less body weights loss than animals receiving vehicle. Body weights in
Kg (a and b) and in percentage (c and d) are shown for the 100 ng/Kg and 250 ng/Kg dose groups. Monkeys were subjected to an LD50/30 of TBI at
day 0 and subsequently received either vehicle (P5.6TT) or HemaMax subcutaneously at the indicated dosing regimens. Supportive care was
prohibited during the study. Body weights were recorded every other day for up to day 30.
doi:10.1371/journal.pone.0030434.g013
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differentiation of the surviving stem cells following radiation
exposure, leading to hematopoietic regeneration (Figure 14).
Activation of osteoblasts appears to be crucial for the survival,
expansion, and homing of hematopoietic stem cells and megakar-
yocytes [70–75]. It has been shown that exposure to lethal doses of
radiation leads to a specific expansion of osteoblastic niche,
whereby the surviving pool of radioresistant osteoprogenitors
proliferates close to the endosteal bone areas [76]. The relatively
long-lived, surviving megakaryocytes were also observed close to
the endosteal surface of trabecular bone rather than in their
normal parasinusoidal site. Megakaryocytes release factors that
stimulated the expansion of osteoblastic niche [76]. Consistent
with these findings, immunohistochemical examinations in our
study revealed a similar cellular configuration in mice bone
marrow, showing cellular islands consisting of osteoblastic niche,
megakaryocytes, and hematopoietic stem cells close to the bone. In
CD34+, IL-12Rb2–positive bone marrow cells, HemaMax
increases EPO secretion while, in contrast to its traditional action
in mature lymphocytes, it decreases IFN-c secretion [unpublished
data from our lab], providing a milieu that promotes expansion of
hematopoietic stem cells, eventually leading to regeneration of
Figure 14. A multilevel model of HemaMax mechanism of action in increasing survival following exposure to radiation. Current
evidence suggests that HemaMax triggers responses at, at least, 4 levels in the body. At the Level 1 response, HemaMax promotes proliferation and
activation of extant, radiosensitive immune cells, namely NK cells, macrophages, and dendritic cells. HemaMax-induced plasma elevations of IL-15
and IL-18 also facilitate maturation of NK cells, leading to the release of IFN-c, which in turn, positively affects the production of endogenous IL-12
from macrophages and dendritic cells, and perhaps NK cells. These events enhance the innate immune competency early on following HemaMax
administration. At the Level 2 response, HemaMax promotes proliferation and differentiation of the surviving hematopoietic stem cells, osteoblasts,
and megakaryocytes into a specific cellular configuration that ensues optimal hematopoiesis. HemaMax-induced secretion of EPO from CD34+, IL-
12Rb2–positive bone marrow cells may also suppress local over-production of IFN-c in the bone marrow and, thus, provide a milieu that promotes
expansion of hematopoietic cells. Hematopoietic regeneration in the bone marrow enhances both innate and adaptive immune competency. At the
Level 3 response, HemaMax preserves GI stem cells, leading to a reduction in pathogen leakage, an increase in food consumption, and a decrease in
diarrhea. At the Level 4 response, HemaMax likely directly increases renal release of EPO, a cytoprotective factor, which enhances cellular viability in a
diverse set of organs/tissues. Continued production of endogenous IL-12 primarily from dendritic cells activated by pathogens and/or EPO serves as a
positive feedback loop and plays a key role in sustaining the initial response to exogenous HemaMax, perhaps for weeks after radiation. q=increase;
Q=decrease; HSC=Hematopoietic stem cells; NK cells=natural killer cells.
doi:10.1371/journal.pone.0030434.g014
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EPO also contributes to the development of such optimal milieu
by suppressing the over-production of inflammatory cytokines
such as IFN-c, IL-6, IL-2, and TNF-a from T cells [29]. Inhibition
of IFN-c production by EPO is in agreement with our findings
showing that plasma IFN-c levels were suppressed in irradiated
mice at a HemaMax dose (20 ng/mouse) that substantially
increased plasma EPO levels. Furthermore, the increased plasma
EPO concentrations may, at least in part, explain the lack of
increases in monkey plasma levels of proinflammatory cytokines
suchas IL-2, IL-6, and TNF-a following HemaMax administration.
HemaMax initiates the Level 3 Response by preserving GI stem
cells, which regenerate intestinal crypt cells and ensure intestinal
integrity (Figure 14). HemaMax-induces intestinal cell-cell border
integrity, which reduces pathogen leakage, increases food
absorption, and decreases diarrhea. The reduction of ‘‘leaky gut
syndrome’’ provides further immune-related benefit by decreasing
pathogen entry into peripheral blood circulation (Figure 14).
HemaMax-induced GI recovery thus provides a greater chance of
survival following lethal radiation exposure.
HemaMax initiates the Level 4 Response by increasing plasma
levels of EPO, likely by enhancing EPO release from the kidneys
following direct activation of its renal receptors. Given its
antioxidant, anti-inflammatory, and antiapoptotic activities, EPO
acts as a general cytoprotective factor in the body, enhancing
cellular viability in a diverse set of organs/tissues including the
brain, peripheral nerves, heart, kidney, skin, and intestine [77].
EPO may also preserve key cells involved in Level 1 and 2 survival
advantages of HemaMax, namely niche bone marrow cells, as well
as mature and immature dendritic cells, macrophages, and NK
cells against radiation toxicity. Matured dendritic cells may also
release IL-12 in response to EPO [56,57] and/or IFN-c [78],
providing a positive feedback loop that amplifies the events
originally initiated by exogenous administration of HemaMax.
Finally, continuous generation of endogenous IL-12 induced by
a single dose of exogenous HemaMax in irradiated, immunocom-
promised hosts is another key survival advantage. Continuous
endogenous production of IL-12 is primarily a result of the Level 1
HemaMax-induced response. In addition, bacterial and patho-
genic products gaining access to the circulation following radiation
injury can activate dendritic cells to promote innate and adaptive
responses, and further lead to a release of endogenous IL-12.
Thus, we hypothesize that HemaMax promotes proliferation of
surviving immune cells, cells of the bone marrow niche, namely
osteoblasts and megakaryocytes, hematopoietic stem cells, and
provides protection against radiation injury to key intestinal stem
cells through various feedback loops. These feedback loops
promote the generation of soluble factors such as endogenous
IL-12, IFN-c, and EPO, allowing regeneration of hematopoietic
system and recovery of immune and GI functions (Figure 14).
The studies reported here culminate with the important finding
from several proof of concept studies, where we demonstrate for
the first time that HemaMax mitigates radiation-induced injury in
NHP, an animal model that is closely related to human.
Importantly, for the FDA Animal Rule path to approval,
allometric dose conversion from mice to rhesus monkey allowed
identification of comparable doses that provided similar Hema-
Max exposure in monkeys. Despite similar PK characteristics, the
IFN-c response to HemaMax appeared to be stronger in monkeys
compared to mice. The fact that the percentage of survival of
rhesus monkeys was similar after receiving either a single dose or
two doses of HemaMax at either 100 ng/Kg or 250 ng/Kg
suggest that HemaMax is likely to be effective at even lower doses.
Importantly, the HemaMax doses used in the NHP studies
correspond to human doses of about 30 ng/Kg and 80 ng/Kg,
respectively. In cancer patients, IL-12 has been administered
intravenously, intraperitoneally, or subcutaneously at a dose range
of 3 ng/Kg to 600 ng/Kg as a monotherapy or part of a
combination therapy for the treatment of various carcinomas [34–
36,79,80]. Intravenously, IL-12 has been associated with a high
rate of toxicity [79]. Intraperitoneally, IL-12 reaches dose limiting
toxicity (elevated transaminase) at 600 ng/Kg and is most
frequently associated with fever, fatigue, abdominal pain, and
nausea [80]. Subcutaneously, IL-12 is generally well tolerated
when it is administered twice weekly at a range of 300 ng/Kg to
500 ng/Kg for up to 3 years [36]. In our studies, HemaMax was
also well tolerated in monkeys after a single dose or up to seven
doses of 1000 ng/Kg (data not shown) with no overt sign of
toxicity.
Our safety studies in monkeys, coupled with the very low
effective dose in both mice and monkeys, indicate that the requisite
HemaMax dose for radiomitigation will be substantially lower
than the IL-12 doses previously used in cancer patients, thus
suggesting a more favorable safety profile for HemaMax in
radiation victims Given the expected safety profile for HemaMax,
it is envisioned that the drug could be disseminated to all
individuals in the vicinity of a radiological event, even in the
absence of any knowledge of the actual level of radiation exposure.
Currently, a First-in-Human (FIH) study in healthy volunteers is
ongoing.
Although the roles of IL-12 in immunity and cancer were the
subject of intensive study in several clinical trials, IL-12 was never
approved as a drug for any indication. The reason for the lack of
advancement of IL-12 to approval was its modest clinical activity
and significant toxicity due to high and repeated dosing regimens
[15,81]. As shown in this study, potent radiomitigation effects in
mice and NHP can be achieved using very low, nanogram per
kilogram doses of HemaMax given merely once. The single, very
low dose of HemaMax required for its radiomitigation effects
underscores both its potency and its expected safety in humans.
In an era of the increased risk for radiological terrorism or
accident, medical contingency plans and preparedness are crucial
to saving lives. The major components of such plans are the
detection of radiation exposure, rapid determination of the
absorbed radiation doses, and availability of the validated
radiation mitigators [82]. Doubtlessly, effective radiomitigators
are the key to the preparedness success. Our findings indicate that
HemaMax may serve as a novel intervention for use as a frontline
treatment to mitigate death due to radiation injury. First-in-
Human, phase I studies are ongoing to assess the safety and
pharmacokinetic and pharmcodynamic profiles of HemaMax,
along with further efficacy studies in animals. The culmination of
these human and animal studies will allow a determination of the
predictive efficacious dose of HemaMax in humans under the
Animal Rule, where efficacy is determined in animal models and
safety is determined in humans.
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